ClinicalTrials.gg
CompletedNCT01962792Updated Dec 21, 2021Results posted

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

A Phase 1/2 interventional study of Ibrutinib and Carfilzomib in Multiple Myeloma, sponsored by Pharmacyclics LLC.. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-21.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
31st of 113
84 · median 54
Started
2013
with 13 others
Phase 1/2
28 of 113
3 open now
Registered
41st of 113
by date

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 31st largest by enrollment, is one of 14 that started in 2013, is one of 28 in phase 1/2, and was the 41st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

A MULTICENTER PHASE 1/2B STUDY OF THE BRUTON'S TYROSINE KINASE INHIBITOR, IBRUTINIB (PCI-32765), IN COMBINATION WITH CARFILZOMIB (KYPROLIS™) IN SUBJECTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA

Read the detailed description

Bruton's tyrosine kinase (Btk) is an enzyme that is present in hematopoietic cells other than T cells and is necessary for downstream signal transduction from various hematopoietic receptors including the B cell receptor as well as some Fc, chemokine, and adhesion receptors, and is crucial for both B cell development and osteoclastogenesis. Although down-regulated in normal plasma cells, Btk is highly expressed in the malignant cells from many myeloma patients and some cell lines. PCI-32765 is a potent and specific inhibitor of Btk currently in Phase 2 and 3 clinical trials. The current study is designed and intended to determine the safety and efficacy of PCI-32765 in combination with carfilzomib (Kyprolis™) with and without dexamethasone in subjects with relapsed or relapsed and refractory multiple myeloma (MM).

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • PCI-32765
  • Multiple Myeloma
  • Relapsed Refractory Multiple Myeloma
  • Bruton's Tyrosine Kinase
  • Carfilzomib
  • Dexamethasone
  • Ibrutinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • of MM as defined by at least ONE of the following:

    1. Serum monoclonal protein (SPEP) ≥1 g/dL
    2. Urine M-protein ≥200 mg/24 hrs
    3. Serum free light chain (SFLC): involved FLC ≥10 mg/dL (≥100 mg/L) AND abnormal kappa to lambda serum free light chain ratio
  • or relapsed and refractory MM after receiving at least 2 previous therapies, including an immunomodulator and bortezomib and had either no response or documented disease progression (according to IMWG criteria) to the most recent treatment regimen
  • Adequate hematologic, hepatic, and renal function
  • performance status of 0-2

Inclusion Criteria for Phase 2 Sub-study Cohort:

  • Must meet all inclusion criteria defined in main study and in addition the following criteria must be met:
  • Subject must have received a regimen containing carfilzomib in combination with dexamethasone as their most recent and have:

    1. Achieved less than a partial response (\<PR) following at least 4 cycles and are without evidence of progression disease (PD).

      OR

    2. Disease progression following an initial confirmed response of MR or better to the combination (according to IMWG response criteria).

Exclusion Criteria:

  • Subject must not have primary refractory disease
  • Plasma cell leukemia, primary amyloidosis or POEMS syndrome
  • Unable to swallow capsules or disease significantly affecting gastrointestinal function
  • Requires anti-coagulation with warfarin or a vitamin K antagonist
  • Requires treatment with strong inhibitors

Exclusion Criteria for Phase 2 Sub-study Cohort:

  • Must not meet any exclusion criteria defined in main study except for exclusion criteria "Subject must not have primary refractory disease" which is related to prior carfilzomib
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Phase 1 - Dose Finding

    Ibrutinib PO 560mg + Carfilzomib IV 20/27mg/m2 + Dexamethasone PO 20mg

    Drug: Ibrutinib · Drug: Carfilzomib · Drug: Dexamethasone

  • Experimental
    Phase 2b - Main Study

    Ibrutinib PO 560mg + Carfilzomib IV 20/36mg/m2 + Dexamethasone PO 20mg

    Drug: Ibrutinib · Drug: Carfilzomib · Drug: Dexamethasone

  • Experimental
    Phase 2b - Sub-study

    Ibrutinib PO 840 mg + Carfilzomib IV 20/36 mg/m2 + Dexamethasone PO 20 mg

    Drug: Ibrutinib · Drug: Carfilzomib · Drug: Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    -To evaluate the overall response (ORR) of ibrutinib in combination with carfilzomib and dexamethasone.

    Time frame: up to 4 years

Secondary outcomes

  1. Duration of Response (DOR)

    The time interval between the date of initial documentation of a response (PR or better) and the date of first documented evidence of progressive disease, death, or date of censoring for the subjects who had not progressed/died. The censoring date was the last adequate tumor assessment date.

    Time frame: Up to 4 years

  2. Overall Survival

    Time from date of first dose of study treatment to the date of death from any cause

    Time frame: Up to 4 years

  3. Progression Free Survival (PFS)

    Time from date of first dose of study treatment to the date of first documented evidence of progressive disease, death or date of censoring for the subjects not progressed/died. The censoring date was the last adequate tumor assessment date.

    Time frame: Up to 4 years

07

Results

Posted Dec 21, 2021

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 (560 mg)Cohort 2a (560 mg)Cohort 2b (560 mg)All RP2D (840 mg)
Started351759
Completed351759
Not completed0000

Outcome measures

PrimaryOverall Response Rate (ORR)

-To evaluate the overall response (ORR) of ibrutinib in combination with carfilzomib and dexamethasone.

Time frame:
up to 4 years
Reported as:
Count of participants · Participants
Overall Response Rate (ORR)
ParticipantsCohort 1 (560 mg)Cohort 2a (560 mg)Cohort 2b (560 mg)All RP2D (840 mg)
Overall Response Rate (ORR)221242
SecondaryDuration of Response (DOR)

The time interval between the date of initial documentation of a response (PR or better) and the date of first documented evidence of progressive disease, death, or date of censoring for the subjects who had not progressed/died. The censoring date was the last adequate tumor assessment date.

Time frame:
Up to 4 years
Reported as:
Median · Months
Duration of Response (DOR)
MonthsCohort 1 (560 mg)Cohort 2a (560 mg)Cohort 2b (560 mg)All RP2D (840 mg)
Duration of Response (DOR)7.1 (1.2 to 13.0)15.3 (5.4 to 15.3)9.2 (3.0 to 14.5)7.2 (2.7 to 16.6)
SecondaryOverall Survival

Time from date of first dose of study treatment to the date of death from any cause

Time frame:
Up to 4 years
Reported as:
Median · Months
Overall Survival
MonthsAll RP2D (840 mg)
Overall Survival35.9 (0.9 to 51.8)
SecondaryProgression Free Survival (PFS)

Time from date of first dose of study treatment to the date of first documented evidence of progressive disease, death or date of censoring for the subjects not progressed/died. The censoring date was the last adequate tumor assessment date.

Time frame:
Up to 4 years
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsAll RP2D (840 mg)
Progression Free Survival (PFS)7.4 (4.6 to 10.2)

Adverse events

Collected over 4 years, 2months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 (560 mg)0/3 (0%)2/3 (66.7%)3/3 (100%)
Cohort 2a (560 mg)4/5 (80%)5/5 (100%)5/5 (100%)
Cohort 2b (560 mg)9/17 (52.9%)17/17 (100%)17/17 (100%)
All RP2D (840 mg)22/59 (37.3%)59/59 (100%)58/59 (98.3%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventCohort 1 (560 mg)Cohort 2a (560 mg)Cohort 2b (560 mg)All RP2D (840 mg)
PneumoniaInfections and infestations1/32/51/176/59
Atrial FlutterCardiac disorders1/30/50/171/59
ConstipationGastrointestinal disorders0/31/50/170/59
DiarrhoeaGastrointestinal disorders0/31/52/170/59
AstheniaGeneral disorders0/31/50/170/59
Clostridium difficile colitisInfections and infestations0/31/50/171/59
Gastrointestinal infectionInfections and infestations0/31/50/171/59
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/31/50/171/59
Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/31/50/170/59
Non - small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/31/50/170/59
Most frequent other events
Showing 10 of 391
Most frequent other events
EventCohort 1 (560 mg)Cohort 2a (560 mg)Cohort 2b (560 mg)All RP2D (840 mg)
FatigueGeneral disorders0/34/512/1727/59
DiarrhoeaGastrointestinal disorders0/33/511/1729/59
AnaemiaBlood and lymphatic system disorders1/33/56/1724/59
PyrexiaGeneral disorders1/33/58/1712/59
ChillsGeneral disorders0/33/51/177/59
ArthralgiaMusculoskeletal and connective tissue disorders0/33/50/1710/59
Peripheral sensory neuropathyNervous system disorders0/33/53/1713/59
EpistaxisRespiratory, thoracic and mediastinal disorders0/33/55/1710/59
ThrombocytopeniaBlood and lymphatic system disorders1/31/53/1730/59
HeadacheNervous system disorders1/32/58/1713/59

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1 (560 mg)Cohort 2a (560 mg)Cohort 2b (560 mg)All RP2D (840 mg)Total
<=18 years00000
Between 18 and 65 years01123346
>=65 years3452638
Age, Continuous
Age, Continuous(years)Cohort 1 (560 mg)Cohort 2a (560 mg)Cohort 2b (560 mg)All RP2D (840 mg)Total
Median69.0 ± 1.5372.0 ± 9.2160.0 ± 10.2963.0 ± 9.8663.5 ± 9.88
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (560 mg)Cohort 2a (560 mg)Cohort 2b (560 mg)All RP2D (840 mg)Total
Female11112841
Male2463143
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 (560 mg)Cohort 2a (560 mg)Cohort 2b (560 mg)All RP2D (840 mg)Total
Hispanic or Latino102710
Not Hispanic or Latino25155173
Unknown or Not Reported00011
Region of Enrollment
Region of Enrollment(participants)Cohort 1 (560 mg)Cohort 2a (560 mg)Cohort 2b (560 mg)All RP2D (840 mg)Total
United States35175984
08

Study locations

17 sites
  • City of Hope
    Duarte, California 91010, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • New York Presbyterian Hospital - Weill-Cornell
    New York, New York 10021, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Carolinas Healthcare System
    Charlotte, North Carolina 28204, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • MUSC Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Vanderbilt Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Methodist Healthcare System
    San Antonio, Texas 78229, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • McGill University
    Montreal, Quebec QC H4A 3J1, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Mar 2019, 63 months.

Results were first posted in Dec 2021, 2 years 9 months after primary completion.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's 63 months is close to that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2013
First posted
Oct 14, 2013
StartActual
Dec 2013
Primary completionActual
Mar 2019
CompletionActual
Mar 2019
Results first posted
Dec 21, 2021
Last update
Dec 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01962792
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Oct 14, 2013
Start date
Dec 2013
Primary completion
Mar 2019
Completion
Mar 2019
Results posted
Dec 21, 2021
Last update
Dec 21, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibrutinib · Carfilzomib

Start the discussion